The New York Times (NYT) reported on Dec. 1, 2014 that companies in the biotechnology sector might be the latest victims of computer security breaches.
The New York Times (NYT) reported on Dec. 1, 2014 that companies in the biotechnology sector might be the latest victims of computer security breaches. The perpetrators, who are thought to be former investment bankers, are using the information they glean to obtain a market edge on the pharmaceutical industry.
Silicon Valley security company FireEye unearthed the information about the apparent cyber attacks. Approximately 50% of the businesses affected by the security breach are in the biotechnology sector, with 10% of the companies identified specifically as drug manufacturers. FireEye is the same company that detected the recent Target malware that resulted in a widespread data breach.
NYT says that because the emails appear to be grammatically correct and do not incorporate malware, the phishing attempts are harder to detect.
Jen Weedon, a FireEye threat intelligence manager, told the NYT that the executives being targeted by these cyber attacks have confidential information in their email accounts that could potentially sway market decisions. Weedon said that the hackers are specifically seeking “information protected by attorney-client privilege, safety reports, [and] internal documents about investigations and audits.”
Dan McWhorter, vice-president of threat intelligence at FireEye, said in a press release that these security breaches meant to help hackers play the stock market are fairly novel; it is the first time FireEye is “seeing a group of very sophisticated attackers actually systematically acquire information that only has true value to a criminal when used in relation to the stock market.”
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.